Profusa, Inc. Common Stock (PFSA) Stock Analysis & Winston Score
Profusa is a small medical technology company that makes tiny sensors designed to be injected under the skin. These sensors continuously monitor chemicals in the body — like oxygen or glucose — without needing to draw blood. The main customers are expected to be patients managing chronic conditions, military personnel, and healthcare providers who need real-time data on a person's health. The company earns money by selling its sensor devices and potentially through data or monitoring services, though it remains in an early, pre-revenue stage. Profusa has received funding from DARPA, the U.S. military's research arm, which reflects its focus on both consumer health and defense applications. The financial data above — including zero gross margin and revenue — confirms the company is not yet generating meaningful commercial sales. The biggest risk is that Profusa must successfully complete clinical trials and win regulatory approval before it can sell its products widely, which requires significant time and continued outside funding.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Data not available (0/30)
- Growth: Weak (1/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $1.73
Market Cap: $0M
Sector: Healthcare
Industry: Medical - Equipment & Services
